Why Most Antimicrobial Peptides Fail Clinically — And What It Takes to Succeed | Research

The takeaway

Despite extensive preclinical success, most AMPs fail clinical translation due to pharmacokinetic limitations, dosing constraints, and wrong indication selection, with AI-guided design showing promise but not yet bridging the in vitro-to-in vivo gap.

Most fail clinically
Despite thousands of AMPs studied and proven effective in vitro, very few have reached clinical approval due to pharmacokinetic and translational challenges

What the researchers found

Most AMPs fail clinically due to pharmacokinetic limitations, dosing constraints, and indication selection rather than lack of antimicrobial activity, with AI-guided design improving discovery but not yet solving the in vitro-to-in vivo efficacy gap.

Why it matters

Understanding why AMPs fail clinically is essential for designing ones that succeed. This review provides a framework for translating promising lab compounds into real drugs.

How the study worked

Comprehensive review integrating mechanistic insights, clinical trial outcomes (successes and failures), pharmacokinetic considerations, and evaluation of computational/AI-guided AMP design platforms.

What this study cannot tell us

Cannot cover all AMP candidates comprehensively. Some failures may have unreported details. AI tools are evolving rapidly and conclusions may soon be outdated.

How to read the evidence

Comprehensive conceptual review integrating clinical outcomes, pharmacokinetics, and AI design evaluation. Authoritative analysis of the field's translational challenges.

When this study was published

Published in 2025.

The bigger picture

This is a sobering but essential reality check for the AMP field, providing actionable principles for the next generation of clinically viable peptide antimicrobials.

Questions still open

What AMP properties best predict clinical success?
Can AI design AMPs optimized for in vivo pharmacokinetics rather than just in vitro activity?
Which infection indications offer the best chance of AMP clinical success?

Common questions

Why haven't antimicrobial peptides become common antibiotics?

They work well in the lab but struggle in the body — they break down too quickly, get cleared before reaching infection sites, and haven't been tested in the right diseases. The few that succeeded are used topically or in specific niches.

Can AI fix the antimicrobial peptide problem?

AI is speeding up discovery of promising AMPs but hasn't yet solved the core problem: what works in a test tube often doesn't work in a living body. AI is starting to address pharmacokinetics, but this remains the biggest challenge.

Read the original research

Decoding antimicrobial peptides: An insight into their discovery, classifications, structures, and applications.

Microbial pathogenesis, 214, 108421

View on PubMed ↗Publisher’s paper ↗

Citation

Fu, Qifu; Yan, Bohu; Xu, Jialin; Ding, Yuqi; Chen, Xiaojun; Wang, Yanan; Sun, Zhiliang; Li, Jiyun. (2026). Decoding antimicrobial peptides: An insight into their discovery, classifications, structures, and applications.. Microbial pathogenesis, 214, 108421. https://doi.org/10.1016/j.micpath.2026.108421